Les Rosoph, MD, CM, CCFP, (EM), FRCPC

North Bay Dermatology Centre
500 Cassells Street
North Bay, Ontario, Canada
P1B 3Z7


Specialty: Dermatology


Research Interests: Acne, Actinic Keratosis, Atopic Dermatitis, Onychomycosis, Psoriasis, Psoriatic Arthritis, Rosacea

Dr. Les Rosoph is a board certified dermatologist who has been practicing dermatology in North Bay, Ontario since 2001. Dr. Rosoph was also trained in Emergency Medicine. Dr. Rosoph serves as an Assistant Professor of Internal Medicine at the Northern Ontario School of Medicine for both Lakehead University and Laurentian University.

At the North Bay Dermatology Centre, Dr. Rosoph has been conducting clinical trials since 2002. Dr. Rosoph has been involved with over 80 clinical trials in dermatology for indications including psoriasis, psoriatic arthritis, eczema (atopic dermatitis), nail fungus (onychomycosis), actinic keratosis, seborrhea, and acne. North Bay Dermatology Centre services a large section of Northern Ontario including Sudbury, Timmins, and even Sault Ste. Marie.

A regulatory inspection was held at Dr. Rosoph’s site for a pivotal phase III study that he conducted. The site did not receive a form 483 and no significant findings were noted in that inspection. Due to Dr. Rosoph's quality of work and experience in clinical research he has also authored many articles including a publication in the Lancet.


Click to view Dr. Les Rosoph's Publications

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016 Dec 15; 375(24): 2335-48. Epub 2016 Sep 30. PMID: 27690741

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015 Oct; 173(4): 949-61. PMID: 26149717 / doi: 10.1111/bjd.14018

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 Aug 8; 386(9993):541-51. Epub 2015 Jun 10. PMID: 26072109 / doi: 10.1016/S0140-6736(15)60125-8

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol 2015 Jul; 24(7): 529-35. Epub 2015 May 8. PMID: 25828362 / doi: 10.1111/exd.12710

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015 Feb; 172(2): 484-93. Epub 2014 Dec 11. PMID: 25132411 / doi: 10.1111/bjd.13348

Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014 Nov; 13(11): 1380-6. PMID: 25607706

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013 Aug 31; 382(9894):780-9. Epub 2013 Jun 13. PMID: 23769296 / doi: 10.1016/S0140-6736(13)60594-2

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet 2012 Aug 25; 380(9843): 738-46. Epub 2012 Jun 29. PMID: 22748702

Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012 Feb; 66(2): e33-e45. Epub 2010 Sep 17. PMID: 20850895

Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J, Liu Y, Graeber M; Adapalene Lotion Study Group. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2010 Jun; 9(6): 639-646. PMID: 20645525

Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M, Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009 Nov; 161(5): 1180-1189. Epub 2009 May 21. PMID:19466959

Rivers JK, Rosoph, L, Provost N, Bissonnette R. Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head. J Cut Med Surg 2008 May-Jun; 12(3):97-101. PMID:18544290

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 May; 371 (9625): 1675-1684. PMID: 18486740

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 May; 371 (9625): 1665-1674. PMID: 18486739

Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, Shear NH, Huizinga RB, Maksymowych WP. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008 Apr; 371: 1337-1342. PMID: 18424323

Papp KA, Toth D, Rosoph L. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatol 2006 Oct; 6: 9. PMID: 17067371

Rosoph L. Book Review: Dermatology Secrets in Color. J Cut Med Surg 2002 Jun; 3:257.

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.